Cancer incidence worldwide is alarming and among the cancers that affect women ovarian cancer is the most fatal. Many side effects are associated with conventional therapies and none of them are completely effective, so the development of new treatments is necessary. Brazilian red propolis extract is a natural product with complex composition and great potential for cancer treatment. However, its clinical application is harmed due to unfavourable physicochemical characteristics. To enable its application encapsulation in nanoparticles can be used. Objectives: The aims of this work were to develop polymeric nanoparticles with Brazilian red propolis extract and compare their action with the free extract against ovarian cancer cells. Methods: Box Behnken design was used and nanoparticles were characterised using the techniques dynamic light scattering, nanoparticle tracking analysis, transmission electron microscopy, differential scanning calorimetry and encapsulation efficiency. Activity against OVCAR-3 was also tested on 2D and 3D models. Key findings: Nanoparticles’ sizes were ~200 nm with monomodal size distribution, negative zeta potential, spherical shape and with extract molecularly dispersed. Encapsulation efficiency was above 97% for the biomarkers chosen. Nanoparticles had greater efficacy in comparison with free propolis in OVCAR-3. Conclusions: So far, the nanoparticles here described have the potential to be a chemotherapy treatment in the future.
This study evaluates the antimicrobial, antioxidant, and anticancer effects of Brazilian red propolis extract (BRPE) and its nanoencapsulated form (NCBRPE) to address bacteria and conditions associated with the ovarian cancer microenvironment. The NCBRPE showed an average size of 178.3 ± 3.3 nm, a polydispersity index (PdI) of 0.06, and an encapsulation efficiency exceeding 97% for the main bioactive compounds of propolis. Antimicrobial assays revealed that BRPE exhibited minimum inhibitory concentrations (MICs) ranging from 4 to 256 mg/L against seven bacterial strains, while NCBRPE demonstrated sustained efficacy, with a biofilm inhibitory concentration (BIC) of 128 mg/L against Burkholderia cepacia. In clonogenic assays, NCBRPE reduced long-term cancer cell proliferation, achieving a 10-fold decrease in colony formation compared to untreated controls, significantly outperforming BRPE. Flow cytometry indicated that NCBRPE induced apoptosis in 29% ± 0.4 of ovarian cancer cells (OVCAR-3). Additionally, the DPPH assay confirmed the antioxidant activity of NCBRPE, demonstrating that it retained most of the extract’s original antioxidant capacity. This was further supported by oxidative burst assays, which showed a significant reduction in reactive oxygen species (ROS) production in neutrophils. These findings position NCBRPE as a multi-functional therapeutic candidate for managing infections, oxidative stress, and tumor progression in the ovarian cancer microenvironment.